IE31885L - Reducing corticosteroid side-effects - Google Patents
Reducing corticosteroid side-effectsInfo
- Publication number
- IE31885L IE31885L IE680093A IE9368A IE31885L IE 31885 L IE31885 L IE 31885L IE 680093 A IE680093 A IE 680093A IE 9368 A IE9368 A IE 9368A IE 31885 L IE31885 L IE 31885L
- Authority
- IE
- Ireland
- Prior art keywords
- corticosteroid
- compositions
- pyridyl
- side effects
- cortisone
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 8
- 230000000694 effects Effects 0.000 title abstract 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 abstract 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229960004544 cortisone Drugs 0.000 abstract 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- FUFLCEKSBBHCMO-KJQYFISQSA-N 11-dehydrocorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 FUFLCEKSBBHCMO-KJQYFISQSA-N 0.000 abstract 1
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 abstract 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 abstract 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229960002478 aldosterone Drugs 0.000 abstract 1
- -1 alkyl alkylamines Chemical class 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 229960001334 corticosteroids Drugs 0.000 abstract 1
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 229960000258 corticotropin Drugs 0.000 abstract 1
- 229960003957 dexamethasone Drugs 0.000 abstract 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 abstract 1
- 125000005265 dialkylamine group Chemical group 0.000 abstract 1
- 239000006196 drop Substances 0.000 abstract 1
- 229940050411 fumarate Drugs 0.000 abstract 1
- 229940050410 gluconate Drugs 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000002674 ointment Substances 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 abstract 1
- 229960004618 prednisone Drugs 0.000 abstract 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 abstract 1
- 229940074404 sodium succinate Drugs 0.000 abstract 1
- 229910021653 sulphate ion Inorganic materials 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
- 229940095064 tartrate Drugs 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
1,175,482. Corticosteroid compositions. UNIMED Inc. 15 Jan., 1968 [9 March, 1967], No. 2078/68. Heading A5B. Corticosteroid compositions with reduced corticosteroid side effects comprise a corticosteroid and at least one compound selected from beta-(2- or 4- pyridyl) alkyl alkylamines and dialkylamines; 1-(2<SP>1</SP>- or 41-pyridyl)-2, 3- cis- or trans-dicarboxylic acid cyclobutanes; alphapicolinic acid dialkylamides; and non- toxic acid addition salts thereof. Examples of anti-inflammatory corticosteroids include cortisone, cortisone phosphate, hydrocortisone and the acetate and 21-sodium succinate thereof, prednisone, dexamethasone and the sodium phosphate salt thereof, ACTH, corticosterone, 11-dehydrocorticosterone, 11-desoxycorticosterone and aldosterone. Suitable salts include the hydrochloride, sulphate, tartrate, fumarate and gluconate. The compositions may be administered orally, parenterally or topically in the form of tablets, ampoules, drops, suspensions or ointments. Corticosteroid side effects are reduced by administering to a non-human animal simultaneously with, before or after administration of the corticosteroid at least one of the above-mentioned compounds.
[GB1175482A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62179167A | 1967-03-09 | 1967-03-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE31885L true IE31885L (en) | 1968-09-09 |
| IE31885B1 IE31885B1 (en) | 1973-02-07 |
Family
ID=24491653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE93/68A IE31885B1 (en) | 1967-03-09 | 1968-01-23 | Reduction of corticosteroid side effects |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3474168A (en) |
| BE (1) | BE710504A (en) |
| DE (1) | DE1667925A1 (en) |
| FR (1) | FR7356M (en) |
| GB (1) | GB1175482A (en) |
| IE (1) | IE31885B1 (en) |
| IL (1) | IL29319A (en) |
| NL (1) | NL6801136A (en) |
| SE (1) | SE347874B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4353896A (en) * | 1981-06-08 | 1982-10-12 | Levy Michael A | Penetrating topical medicament |
| US4945089A (en) * | 1987-12-29 | 1990-07-31 | Alcon Laboratories, Inc. | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids |
| US5358943A (en) * | 1987-12-29 | 1994-10-25 | Clark Abbot F | Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids |
| US20060074063A1 (en) * | 1995-12-29 | 2006-04-06 | Fernandez-Pol Jose A | Pharmacological agent and method of treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2794763A (en) * | 1955-01-27 | 1957-06-04 | Pfizer & Co C | Pressor amines |
| US3105010A (en) * | 1959-06-19 | 1963-09-24 | Schering Corp | Steroid-amino acid compositions for preventing negative nitrogen balance |
| US3415833A (en) * | 1964-04-16 | 1968-12-10 | Unimed Inc | Pyridyl-dicarboxylic acid cyclobutane derivatives |
| US3984304A (en) * | 1974-11-11 | 1976-10-05 | Ppg Industries, Inc. | Electrode unit |
-
1967
- 1967-03-09 US US621791A patent/US3474168A/en not_active Expired - Lifetime
-
1968
- 1968-01-15 DE DE19681667925 patent/DE1667925A1/en active Pending
- 1968-01-15 GB GB2078/68A patent/GB1175482A/en not_active Expired
- 1968-01-17 IL IL29319A patent/IL29319A/en unknown
- 1968-01-19 SE SE00763/68A patent/SE347874B/xx unknown
- 1968-01-23 IE IE93/68A patent/IE31885B1/en unknown
- 1968-01-25 NL NL6801136A patent/NL6801136A/xx unknown
- 1968-02-08 BE BE710504D patent/BE710504A/xx unknown
- 1968-02-20 FR FR140522A patent/FR7356M/fr not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| DE1667925A1 (en) | 1971-07-22 |
| SE347874B (en) | 1972-08-21 |
| NL6801136A (en) | 1968-09-10 |
| GB1175482A (en) | 1969-12-23 |
| FR7356M (en) | 1969-10-20 |
| IE31885B1 (en) | 1973-02-07 |
| US3474168A (en) | 1969-10-21 |
| IL29319A (en) | 1971-11-29 |
| BE710504A (en) | 1968-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69231280T2 (en) | Use of sulphamate derivatives as STEROID SULFATASE INHIBITING COMPOUNDS | |
| EP0310541B1 (en) | Antigestagenic and antioestrogenic compounds for the introduction of labour and interruption of pregnancy, as well as for the treatment of gynecologic disorders | |
| WO1996003130A1 (en) | Use of a progesterone antagonist and of a gestagen for the treatment of endometriosis or leiomyomata uteri | |
| GB1171509A (en) | Pyridine Derivatives | |
| DE60018707T2 (en) | ANTI-ANDROGENES AND METHOD FOR THE TREATMENT OF DISEASES | |
| Makman et al. | Inhibitory effects of cortisol and antibiotics on substrate entry and ribonucleic acid synthesis in rat thymocytes in vitro | |
| Gyermek | Pregnanolone: a highly potent, naturally occurring hypnotic-anesthetic agent. | |
| IE31885B1 (en) | Reduction of corticosteroid side effects | |
| Derelanko et al. | Effect of corticosteroids on indomethacin-induced intestinal ulceration in the rat | |
| DE2429101B2 (en) | ALPHA-ISOMERES OF 2-CHLORINE-9-ANGLE BRACKETS ON 3 '- (N'-2-HYDROXYAETHYLPIPERAZINONE) -PROPYLIDEN ANGLE BRACKETS FOR -THIOXANTHENS AND ITS ESTER, PROCESS FOR THEIR EXTRACTION AND MANUFACTURING AND MEANS INCLUDING THESE COMPOUNDS | |
| GB1270614A (en) | Stable aqueous steroid phosphate solutions | |
| DE19849737A1 (en) | Combination agent for the treatment of inflammatory bowel disease | |
| GB1276812A (en) | Novel aminopiperidines, processes for their preparation, and compositions incorporating them | |
| GB1246117A (en) | Pharmaceutical preparations containing glucose compounds, glucose derivatives and process for their manufacture | |
| Tonelli | Acute toxicity of corticosteroids in the rat | |
| Jenkins | An inhibitor of adrenal steroid 11-hydroxylation | |
| US3657435A (en) | 17beta-hydroxy - 17 - ethynyl-4-androsteno(3 2-c) -2'-(p-fluorophenyl)pyrazole and compositions containing same | |
| DE2539824A1 (en) | PHARMACEUTICAL PREPARATION | |
| DE2348197C3 (en) | Norethisteron-O-alkyloxime, process for their preparation and their use | |
| EP0966289B1 (en) | Budesonide for the treatment of cholestatic liver diseases | |
| DE3805064A1 (en) | PHARMACEUTICAL PREPARATIONS FOR INITIATING BIRTH, FOR PREGNANCY AND FOR USE AS A CONCEPT | |
| DE2146239A1 (en) | New contraceptive means | |
| DE940060C (en) | Process for the production of aqueous solutions of drugs that are poorly soluble in water | |
| Krayer et al. | Studies on veratrum alkaloids. XIV. The antiaccelerator cardiac action of derivatives of veratramine and jervine and of synthetic steroid secondary alkamines obtained from pregnenolone and from sapogenins | |
| GB794488A (en) | Therapeutic composition |